Thursday, March 24, 2022 11:36:24 AM
We’ll wrap up with a clinical-stage bioscience researcher, Kezar Life Sciences. This company is involved in the fields of oncology and immunology, and is developing new treatments for cancers and autoimmune diseases. The company’s pipeline features first-in-class small molecule drug therapies with activity in protein degradation and protein secretion.
Kezar’s pipeline features two clinical-stage drug candidates, KZR-261 and KZR-616. The first of these has recently advanced from the discover stage and the company has initiated a Phase 1 open-label dose-escalation study. The drug candidate is being studies as a potential treatment for solid tumor cancers.
The real excitement for this company comes from the two Phase 2 trials of KZR-616. This is an autoimmune drug, under investigation as a treatment for Lupus, among other conditions. The company in December released interim results from its MISSION trial of KZR-616, showing that the drug candidate demonstrated clinically meaningful benefits in patients suffering from Lupus nephritis. The patient pool was small, only 5, but 4 patients showed positive results. In addition, the drug continued to show a ‘favorable’ profile for safety and tolerability, extended over 6 months. Top-line data from the MISSION trial expected in 2Q22.
Kezar also has the PRESIDIO trial ongoing, investigating KZR-616 against active dermatomyositis (DM) or polymyositis (PM). The Phase 2 trial is described as a ‘randomized, placebo-controlled, double-blind, cross-over clinical trial,’ and has enrolled 24 patients. Topline data from PRESIDIO is also expected in the second quarter of this year.
Finally, Kezar has recently announced that it has selected ‘zetomipzomib’ as a brand name for KZR-616.
Kezar also shows a recent ‘million +’ insider trade. Franklin Berger, of the company’s Board, made a purchase worth $1.299 million earlier this week. His buy totaled 80,000 shares, and it brought his stake in Kezar up to an impressive $14.28 million.
This stock has attracted the notice of H.C. Wainwright analyst Raghuram Selvaraju, who points out that the multiple upcoming catalysts are a strong inducement for investors. Selvaraju writes, “In our view, positive data for zetomipzomib from both the MISSION and PRESIDIO trials ought to establish Kezar as a triple-threat across SLE/LN, DM and PM and position the compound for advancement into late-stage clinical development. Depending upon the strength of the data, Kezar might also ultimately be considered an attractive potential acquisition target, in our opinion.”
Recent KZR News
- Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 05/06/2024 08:05:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/08/2024 08:01:00 PM
- Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update • Business Wire • 03/14/2024 08:01:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 03/08/2024 09:05:00 PM
- Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 09:01:00 PM
- Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis • Business Wire • 02/26/2024 11:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:50:01 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 09:56:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:36:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:28:24 PM
- Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • Business Wire • 11/21/2023 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:13:05 PM
- Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/13/2023 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:25:13 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 11/03/2023 08:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:06:39 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 10/09/2023 09:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:14:37 PM
- Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer • Business Wire • 10/03/2023 08:10:00 PM
- Stocks to Watch: FedEx, Kezar Life Sciences, Transcat • Dow Jones News • 09/21/2023 12:30:00 AM
- Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia • Business Wire • 09/20/2023 10:30:00 PM
- Kezar Life Sciences to Participate in Three Upcoming Investor Conferences • Business Wire • 08/31/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:12:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:06:52 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM